Cipla Limited
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
20
Ending by 2030
Sep 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 4 to 25, 2026 · next Dec 4
- 1 fee due Feb 27, 2027The maintenance fee for Ketorolac for the treatment of cancer (US 10,391,080) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
- 1 fee due Mar 24, 2027The maintenance fee for Pharmaceutical antiretroviral composition (US 10,420,727) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
- 1 fee due May 12, 2027The maintenance fee for Thienopyridine derivative for the treatment of hepatitis C infections (US 10,471,048) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 2 fees due Jun 3 to 10, 2027 · next Jun 3
- 1 fee due Jul 5, 2027The maintenance fee for Antiviral phosphonate analogues and process for preparation thereof (US 9,227,990) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.
- 1 fee due Aug 23, 2027The maintenance fee for Antibacterial aminoglycoside analogs (US 9,266,919) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
- 1 fee due Sep 19, 2027The maintenance fee for Stable pharmaceutical formulations of pemetrexed (US 11,931,362) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,403,844 | Rifaximin In force · Medium confidence | In force | Medium confidence | |
| US 9,877,953 | Rifaximin In force · Low confidence | In force | Low confidence | |
| US 10,702,505 | Rifaximin In force · Low confidence | In force | Low confidence | |
| US 12,109,200 | Rifaximin In force · Low confidence | In force | Low confidence | |
| US 8,822,424 | Antibacterial aminoglycoside analogs In force · From the USPTO record | In force | From the USPTO record | |
| US 9,266,919 | Antibacterial aminoglycoside analogs In force · From the USPTO record | In force | From the USPTO record | |
| US 9,688,711 | Antibacterial aminoglycoside analogs In force · From the USPTO record | In force | From the USPTO record | |
| US 11,117,915 | Antibacterial aminoglycoside analogs In force · From the USPTO record | In force | From the USPTO record | |
| US 8,633,234 | Rifaximin In force · High confidence | In force | High confidence | |
| US 9,993,560 | Rifaximin Complexes In force · High confidence | In force | High confidence |
Also on record, not counted in the 66: 3 patents in force now held by others · 104 lapsed for an unpaid fee · 29 ended at full term · 2 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 7 abandoned · 100 no status recorded